{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:17:32Z","timestamp":1783696652832,"version":"3.55.0"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Preexposure prophylaxis (PrEP) is highly effective at preventing HIV-1 when taken as prescribed; however, barriers to uptake persist.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess clinical practice formulary coverage and PrEP uptake barriers and the association between those factors and cumulative HIV-1 incidence.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Retrospective observational cohort study from January 2021 to December 2023 using US pharmacy claims data from HIV-1\u2013negative adults who received daily oral brand emtricitabine and tenofovir disoproxil fumarate (F\/TDF), generic F\/TDF (gF\/TDF), or emtricitabine and tenofovir alafenamide fumarate (F\/TAF), or intramuscular injection of cabotegravir every 2 months, for PrEP (after a 180-day washout period for previous PrEP use).<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Formulary coverage evaluated by claim rejection reasons, dispensing status (dispensed, rejected, or abandoned), payer types, and copayment costs.<\/jats:p>\n <\/jats:sec>\n \n Main outcomes and measures<\/jats:title>\n HIV-1 incidence was described based on PrEP dispensing status. Logistic regression was used to estimate odds ratios (ORs) and 95% CIs of dispensing PrEP claims across key demographic and formulary characteristics.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Overall, 399\u202f902 individuals with 2\u202f680\u202f545 PrEP claims were analyzed. A total of 348\u202f773 (87.2%) were male; 281\u202f452 (70.4%) were aged 18 to 39 years; 42\u202f549 10.6%] lived in predominantly Hispanic neighborhoods, 4114 [1.0%] lived in predominantly non-Hispanic Asian and Pacific Islander neighborhoods, 20\u202f214 [5.1%] lived in predominantly non-Hispanic Black neighborhoods, and 238\u202f292 [59.6%] lived in predominantly non-Hispanic White neighborhoods). Of 265\u202f833 individuals with 12 or more months of follow-up, 238\u202f271 (89.6%) had 1 or more PrEP claims dispensed (DISP), 17\u202f917 (6.7%) never had PrEP dispensed with 50% or more of claims rejected by payer (ND-R), and 9645 (3.6%) never had PrEP dispensed with more than 50% of claims abandoned (ND-A). Individuals in the ND-R and ND-A groups had higher HIV-1 incidence (662 [3.7%] and 270 [2.8%], respectively) vs the DISP group (4811 [2.0%]). In the DISP group, a 1- to 7-day dispensation delay was associated with higher odds of acquiring HIV-1 (OR, 1.29; 95% CI, 1.13-1.47). Most claims were for gF\/TDF (1\u202f400\u202f389 claims [52.2%]); compared with gF\/TDF, the likelihood of claims being dispensed was lower for other PrEP regimens (brand F\/TDF: OR, 0.36; 95% CI, 0.36-0.37; cabotegravir: OR, 0.52; 95% CI, 0.49-0.55; F\/TAF: OR, 0.93; 95% CI, 0.91-0.95). As cost sharing increased, the likelihood of dispensation decreased. The most common reason for claim rejection was that the product was not covered by the formulary (49\u202f690 rejected claims [29.2%]).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and relevance<\/jats:title>\n In this cohort study, HIV-1 incidence was higher in individuals with abandoned or rejected PrEP claims compared with those with dispensed claims. These findings highlight the importance of targeted strategies to improve PrEP claim dispensation and remove payer barriers to reduce HIV-1 transmission.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.44515","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T16:30:50Z","timestamp":1764865850000},"page":"e2544515","source":"Crossref","is-referenced-by-count":0,"title":["Preexposure Prophylaxis Prescription Dispensation Status and HIV-1 Acquisition"],"prefix":"10.1001","volume":"8","author":[{"given":"Li","family":"Tao","sequence":"first","affiliation":[{"name":"Gilead Sciences Inc, Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Yang","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Gruber","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Mezzio","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woodie","family":"Zachry","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H.","family":"Mayer","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Harvard University, Boston, Massachusetts"},{"name":"The Fenway Institute, Fenway Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"issue":"5","key":"zoi251205r1","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/cid\/ciae143","article-title":"Type 1 human immunodeficiency virus (HIV-1) incidence, adherence, and drug resistance in individuals taking daily emtricitabine\/tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: pooled analysis from 72 global studies.","volume":"79","author":"Landovitz","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"27","key":"zoi251205r2","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi251205r3","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","article-title":"Effectiveness and safety of oral HIV preexposure prophylaxis for all populations.","volume":"30","author":"Fonner","year":"2016","journal-title":"AIDS"},{"issue":"13","key":"zoi251205r9","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women.","volume":"391","author":"Bekker","year":"2024","journal-title":"N Engl J Med"},{"key":"zoi251205r10","article-title":"Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons.","author":"Kelley","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi251205r12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1377\/hlthaff.2021.01119","article-title":"Disparities in uptake of HIV pre-exposure prophylaxis among California Medicaid enrollees.","volume":"41","author":"Harawa","year":"2022","journal-title":"Health Aff (Millwood)"},{"issue":"3","key":"zoi251205r13","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25461","article-title":"National trends in HIV pre-exposure prophylaxis awareness, willingness and use among United States men who have sex with men recruited online, 2013 through 2017.","volume":"23","author":"Sullivan","year":"2020","journal-title":"J Int AIDS Soc"},{"issue":"8","key":"zoi251205r14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.67727","article-title":"Analyzing HIV pre-exposure Prophylaxis and viral suppression disparities: insights from America\u2019s HIV Epidemic Analysis Dashboard (AHEAD) national database.","volume":"16","author":"Oddie-Okeke","year":"2024","journal-title":"Cureus"},{"issue":"5","key":"zoi251205r15","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s12325-020-01295-0","article-title":"Barriers to the wider use of pre-exposure prophylaxis in the United States: a narrative review.","volume":"37","author":"Mayer","year":"2020","journal-title":"Adv Ther"},{"key":"zoi251205r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100738","article-title":"Equity of PrEP uptake by race, ethnicity, sex and region in the United States in the first decade of PrEP: a population-based analysis.","volume":"33","author":"Sullivan","year":"2024","journal-title":"Lancet Reg Health Am"},{"issue":"7","key":"zoi251205r17","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s10461-021-03159-2","article-title":"Multilevel barriers to HIV PrEP uptake and adherence among Black and Hispanic\/Latinx transgender women in Southern California.","volume":"25","author":"Ogunbajo","year":"2021","journal-title":"AIDS Behav"},{"issue":"10","key":"zoi251205r18","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1007\/s10461-019-02502-y","article-title":"Barriers and facilitators of PrEP adherence for young men and transgender women of color.","volume":"23","author":"Wood","year":"2019","journal-title":"AIDS Behav"},{"issue":"6","key":"zoi251205r19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267780","article-title":"Proactive strategies to optimize engagement of Black, Hispanic\/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP).","volume":"17","author":"Cespedes","year":"2022","journal-title":"PLoS One"},{"issue":"9","key":"zoi251205r20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257583","article-title":"Racial and ethnic disparities in HIV diagnoses among heterosexually active persons in the United States nationally and by state, 2018.","volume":"16","author":"Martin","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"zoi251205r21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/15532739.2019.1700203","article-title":"Common barriers to healthcare for transgender people in the U.S. Southeast.","volume":"21","author":"Johnson","year":"2019","journal-title":"Int J Transgend Health"},{"issue":"5","key":"zoi251205r22","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1007\/s11606-022-07995-3","article-title":"Barriers in healthcare for Latinx patients with limited English proficiency-a narrative review.","volume":"38","author":"Escobedo","year":"2023","journal-title":"J Gen Intern Med"},{"issue":"1","key":"zoi251205r23","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12889-024-17726-4","article-title":"Can federal policy help overcome systemically reinforced racial inequities in social determinants of health? An observational study of Georgia and neighboring U.S. states.","volume":"24","author":"Napierala","year":"2024","journal-title":"BMC Public Health"},{"issue":"14","key":"zoi251205r24","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1097\/QAD.0000000000003030","article-title":"Novel population-level proxy measures for suboptimal HIV preexposure prophylaxis initiation and persistence in the USA.","volume":"35","author":"Dean","year":"2021","journal-title":"AIDS"},{"issue":"1","key":"zoi251205r26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA panel.","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"zoi251205r27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1377\/hlthaff.2023.00808","article-title":"Estimating the impact of out-of-pocket cost changes on abandonment of HIV pre-exposure prophylaxis.","volume":"43","author":"Dean","year":"2024","journal-title":"Health Aff (Millwood)"},{"issue":"3","key":"zoi251205r28","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/cid\/ciac009","article-title":"Abandonment of human immunodeficiency virus preexposure prophylaxis prescriptions at retail pharmacies-United States, 2019.","volume":"75","author":"Huang","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"22","key":"zoi251205r29","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1001\/jama.2019.6390","article-title":"Preexposure prophylaxis for the prevention of HIV infection: US Preventive Services Task Force recommendation statement.","volume":"321","author":"Owens","year":"2019","journal-title":"JAMA"},{"key":"zoi251205r35","article-title":"Impact of the United States Preventive Services Task Force guidelines on pre-exposure prophylaxis claims and HIV-1 infection incidence: an interrupted time series with segmented regression analysis (abstract number B5).","author":"Zachry","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"S5","key":"zoi251205r37","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26351","article-title":"OA2405 Switching between oral and injectable pre-exposure prophylaxis (PrEP) regimens in the United States: an investigation of reasons for switching in the real world.","volume":"27","author":"Tao","year":"2024","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"zoi251205r38","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/QAI.0000000000003370","article-title":"Barriers and facilitators to long-acting injectable HIV pre-exposure prophylaxis implementation in primary care since its approval in the United States.","volume":"95","author":"Keddem","year":"2024","journal-title":"J Acquir Immune Defic Syndr"},{"key":"zoi251205r4","unstructured":"World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015. Accessed August 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK327118\/"},{"key":"zoi251205r5","unstructured":"U.S. Food and Drug Administration. Descovy highlights of prescribing information. 2015. Accessed August 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208215s012lbl.pdf"},{"key":"zoi251205r6","unstructured":"U.S. Food and Drug Administration. Truvada highlights of prescribing information. 2004. Accessed August 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021752s035lbl.pdf"},{"key":"zoi251205r7","unstructured":"FDA News Release. FDA approves first injectable treatment for HIV pre-exposure prevention. 2021. Accessed August 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention#:~:text=Today%2C%20the%20U.S.%20Food%20and,risk%20of%20sexually%20acquired%20HIV"},{"key":"zoi251205r8","unstructured":"U.S. Food and Drug Administration. Cabotegravir highlights of prescribing information. 2021. Accessed August 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021752s035lbl.pdf"},{"key":"zoi251205r11","unstructured":"U.S. Food and Drug Administration. Yeztugo highlights of prescribing information. 2025. Accessed August 2025. https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/hiv\/yeztugo\/yeztugo_pi.pdf"},{"key":"zoi251205r25","unstructured":"Centers for Disease Control and Prevention. US Public Health Service: preexposure prophylaxis for the prevention of HIV infection in the United States\u20142021 update: a clinical practice guideline. 2021. Accessed January 2025. https:\/\/stacks.cdc.gov\/view\/cdc\/112360"},{"key":"zoi251205r30","unstructured":"US Department of Health and Human Services. FAQs about Affordable Care Act implementation part 472022. 2021. Accessed August 2025. https:\/\/www.cms.gov\/CCIIO\/Resources\/Fact-Sheets-and-FAQs\/Downloads\/FAQs-Part-47.pdf"},{"key":"zoi251205r31","unstructured":"Centers for Medicare and Medicaid Services. FAQs about Affordable Care Act and Women\u2019s Health and Cancer Rights Act Implementation Part 68. 2024. Accessed August 2025. https:\/\/www.cms.gov\/files\/document\/faqs-implementation-part-68.pdf"},{"key":"zoi251205r32","unstructured":"IQVIA. Longitudinal access and adjudication data (LAAD)\u2014fact sheet. 2023. Accessed August 2025. https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/fact-sheets\/iqvia-longitudinal-access-and-adjudication-data-fact-sheet-2023.pdf"},{"key":"zoi251205r33","unstructured":"MACPAC. Access in brief: experiences in accessing medical care by race and ethnicity. Advising congress on Medicaid and CHIP policy website. 2022. Accessed January 2025. https:\/\/www.macpac.gov\/wp-content\/uploads\/2022\/02\/MACPAC-Access-in-Brief_Race-and-Ethnicity-Feb-2022.pdf"},{"key":"zoi251205r34","unstructured":"Centers for Medicare and Medicaid Services. Medicare monthly enrollment. 2024. Accessed January 2025. https:\/\/data.cms.gov\/summary-statistics-on-beneficiary-enrollment\/medicare-and-medicaid-reports\/medicare-monthly-enrollment"},{"key":"zoi251205r36","unstructured":"Mikulic? M. Proportion of branded versus generic drug prescriptions dispensed in the United States from 2005 to 2021 .Statista. 2024. Accessed August 2025. https:\/\/www.statista.com\/statistics\/205042\/proportion-of-brand-to-generic-prescriptions-dispensed\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2842308\/tao_2025_oi_251205_1783432630.63696.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:00:33Z","timestamp":1783695633000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2842308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.44515","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]}}}